# Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use

> **NCT02307721** · PHASE1,PHASE2 · COMPLETED · sponsor: **Norwegian University of Science and Technology** · enrollment: 12 (actual)

## Conditions studied

- Drug Overdose

## Interventions

- **DRUG:** Intranasal naloxone
- **DRUG:** Intramuscular naloxone
- **DRUG:** Remifentanil
- **DEVICE:** Aptar Unidose

## Key facts

- **NCT ID:** NCT02307721
- **Lead sponsor:** Norwegian University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-04
- **Final completion:** 2015-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307721, "Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02307721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*